AbbVie Inc. (NYSE:ABBV) Shares Sold by Guyasuta Investment Advisors Inc.

Guyasuta Investment Advisors Inc. trimmed its position in shares of AbbVie Inc. (NYSE:ABBV) by 3.9% in the fourth quarter, HoldingsChannel.com reports. The fund owned 31,256 shares of the company’s stock after selling 1,255 shares during the period. Guyasuta Investment Advisors Inc.’s holdings in AbbVie were worth $4,844,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Mather Group LLC. increased its position in AbbVie by 4.7% during the fourth quarter. Mather Group LLC. now owns 39,498 shares of the company’s stock worth $6,121,000 after buying an additional 1,787 shares during the period. Gilbert & Cook Inc. increased its holdings in shares of AbbVie by 9.8% in the fourth quarter. Gilbert & Cook Inc. now owns 9,691 shares of the company’s stock valued at $1,502,000 after purchasing an additional 861 shares during the period. Eagle Wealth Strategies LLC acquired a new position in shares of AbbVie in the fourth quarter valued at approximately $380,000. Blue Chip Partners LLC increased its holdings in shares of AbbVie by 1.3% in the fourth quarter. Blue Chip Partners LLC now owns 179,439 shares of the company’s stock valued at $27,808,000 after purchasing an additional 2,374 shares during the period. Finally, Marco Investment Management LLC increased its holdings in shares of AbbVie by 0.4% in the fourth quarter. Marco Investment Management LLC now owns 127,026 shares of the company’s stock valued at $19,685,000 after purchasing an additional 492 shares during the period. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at AbbVie

In other news, EVP Azita Saleki-Gerhardt sold 52,870 shares of the stock in a transaction that occurred on Wednesday, February 21st. The stock was sold at an average price of $173.71, for a total transaction of $9,184,047.70. Following the sale, the executive vice president now directly owns 243,944 shares in the company, valued at approximately $42,375,512.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CEO Richard A. Gonzalez sold 138,616 shares of the firm’s stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $177.27, for a total value of $24,572,458.32. Following the sale, the chief executive officer now directly owns 519,099 shares in the company, valued at approximately $92,020,679.73. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Azita Saleki-Gerhardt sold 52,870 shares of the firm’s stock in a transaction that occurred on Wednesday, February 21st. The shares were sold at an average price of $173.71, for a total value of $9,184,047.70. Following the completion of the sale, the executive vice president now owns 243,944 shares in the company, valued at $42,375,512.24. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 383,324 shares of company stock worth $67,780,003. 0.25% of the stock is currently owned by company insiders.

AbbVie Trading Up 0.6 %

AbbVie stock traded up $0.90 during trading on Monday, hitting $160.52. The company’s stock had a trading volume of 2,818,478 shares, compared to its average volume of 5,622,067. The stock has a market capitalization of $284.22 billion, a price-to-earnings ratio of 47.49, a P/E/G ratio of 2.03 and a beta of 0.58. The company has a debt-to-equity ratio of 5.02, a quick ratio of 0.76 and a current ratio of 0.87. The stock’s fifty day moving average is $174.59 and its 200 day moving average is $160.90. AbbVie Inc. has a 1-year low of $130.96 and a 1-year high of $182.89.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, April 26th. The company reported $2.31 EPS for the quarter, beating analysts’ consensus estimates of $2.26 by $0.05. The firm had revenue of $12.31 billion during the quarter, compared to the consensus estimate of $11.93 billion. AbbVie had a return on equity of 165.18% and a net margin of 11.02%. AbbVie’s revenue for the quarter was up .7% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.46 earnings per share. As a group, equities research analysts predict that AbbVie Inc. will post 11.19 EPS for the current year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 15th. Shareholders of record on Monday, April 15th will be issued a dividend of $1.55 per share. This represents a $6.20 dividend on an annualized basis and a yield of 3.86%. The ex-dividend date is Friday, April 12th. AbbVie’s dividend payout ratio is presently 183.98%.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. Truist Financial boosted their target price on AbbVie from $180.00 to $195.00 and gave the company a “buy” rating in a report on Tuesday, February 6th. Guggenheim lifted their price target on AbbVie from $188.00 to $190.00 and gave the company a “buy” rating in a research note on Friday, March 22nd. BMO Capital Markets decreased their price target on AbbVie from $195.00 to $180.00 and set an “outperform” rating on the stock in a research note on Monday. Barclays decreased their target price on AbbVie from $195.00 to $187.00 and set an “overweight” rating on the stock in a research report on Monday. Finally, Raymond James boosted their target price on AbbVie from $181.00 to $189.00 and gave the stock an “outperform” rating in a research report on Monday, February 5th. Three equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, AbbVie currently has an average rating of “Moderate Buy” and a consensus target price of $174.31.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.